Financial Performance - The company's operating revenue for Q3 2021 was ¥34,601,672.19, representing an increase of 18.26% compared to the same period last year[3]. - Net profit attributable to shareholders was ¥11,124,808.29, up 47.37% year-on-year[3]. - The net profit excluding non-recurring gains and losses was ¥5,665,964.09, a decrease of 2.65% compared to the previous year[5]. - Basic earnings per share for the period were ¥0.18, an increase of 20.00% compared to the same period last year[5]. - Total operating revenue for the third quarter reached ¥103,339,036.07, an increase of 26.5% compared to ¥81,615,603.08 in the previous year[37]. - Net profit for the period was ¥32,030,335.22, representing a 39% increase from ¥23,056,678.07 in the prior year[38]. - Basic and diluted earnings per share increased to 0.60 from 0.47, representing a growth of 27.66% year-over-year[41]. Assets and Liabilities - The total assets at the end of the reporting period reached ¥720,354,591.75, reflecting a 60.82% increase from the end of the previous year[5]. - Total liabilities increased to ¥157,371,961.84, compared to ¥108,299,999.20 in the previous year, marking a growth of 45.2%[35]. - The total assets of the company reached ¥720,354,591.75, a significant rise from ¥447,939,659.82 year-over-year[33]. - Total current liabilities include accounts payable of 36,646,732.31 and employee compensation payable of 11,090,491.46[52]. Cash Flow - The company's cash flow from operating activities was ¥31,259,323.68, showing a significant increase of 230.85% year-to-date[5]. - Operating cash flow net amount reached 31,259,323.68, up from 9,448,316.70, marking a significant increase of 230.56%[44]. - Total cash inflow from operating activities was 132,688,343.01, compared to 97,253,561.79 in the previous period, reflecting a growth of 36.48%[42]. - Cash outflow from operating activities totaled 101,429,019.33, an increase from 87,805,245.09, which is a rise of 15.43%[44]. - Cash flow from financing activities netted 248,377,268.52, a substantial increase from 20,955,980.62, indicating a growth of 1,184.09%[46]. - The ending balance of cash and cash equivalents was 50,235,962.38, up from 28,852,233.41, showing an increase of 74.48%[46]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 14,382[14]. - Major shareholders include Yuan Yuyu and Xu Tao, each holding 16.53% (10,922,547 shares) of the company[14]. - The company has a total of 4,508,796 shares held by Yuan Meifu, representing 6.82% of the total shares[14]. - The report indicates that the total number of shares with limited sale conditions is 10,922,547 for both Yuan Yuyu and Xu Tao, set to be released on July 26, 2024[20]. - The report highlights that the company is actively managing its shareholder structure and compliance with regulations regarding share sales[19]. Government Support and Funding - The company received government subsidies amounting to ¥1,855,383.01 during the reporting period, which are closely related to its normal business operations[7]. - The company raised a total of RMB 250,048,697.24 from its initial public offering (IPO), with a net amount of RMB 192,877,550.38 after deducting related expenses[25]. - The company adjusted the planned use of raised funds, reducing the investment in the headquarters project from RMB 360,000,000.00 to RMB 172,877,550.38[25]. - Cumulative use of raised funds reached RMB 164,446,780.95, with a remaining balance of RMB 28,609,298.47 in the dedicated account[26]. Research and Development - Research and development expenses increased to ¥14,068,497.76, compared to ¥11,706,352.06 in the previous year, reflecting a growth of 20.2%[38]. - The company plans to allocate RMB 20,000,000.00 for the development of new implantable medical devices[25]. - The company has successfully obtained domestic medical device registration for its absorbable regenerated oxidized cellulose hemostatic product, enhancing its product portfolio and market competitiveness[27]. - The company’s strategic focus on expanding its product applications in the neurosurgery field, aiming to break the long-standing import monopoly in this market[27]. Strategic and Operational Insights - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[34]. - The company’s financial adjustments reflect a proactive approach to align its funding with operational needs and market opportunities[25]. - The report does not indicate any new product launches or technological advancements during this period[21]. - There is no mention of market expansion or mergers and acquisitions in the current report[21]. - The company has not provided a detailed future outlook or performance guidance in the current report[56].
迈普医学(301033) - 2021 Q3 - 季度财报